Lipokinetix: Overview

Modified on 2009/10/14 21:46 by admin
The Food and Drug Administration (FDA) is warning consumers to immediately stop use of the product Lipokinetix, marketed as a dietary supplement (for weight loss) by Syntrax Innovations, Inc. FDA has received multiple reports of persons who developed liver injury or liver failure while using Lipokinetix. The product contains norephedrine (also known as phenylpropanolamine or PPA), caffeine, yohimbine, diiodothyronine, and sodium usniate. FDA is also advising consumers to consult their physician if they are experiencing symptoms possibly associated with this product, particularly nausea, weakness or fatigue, fever, abdominal pain, or any change in skin color.

If you have experienced serious health problems after taking Lipokinetix, it may be important to contact an attorney who can help you protect your legal rights. Please keep in mind that there may be time limits within which you must commence suit.

See Also

  1. Other Supplements: Overview
  2. Digestive Disorders: Overview
  3. Fatigue: Overview
  4. Liver Failure: Overview
  5. Nausea: Overview
  6. Skin Disorders: Overview
  Name Size